88 related articles for article (PubMed ID: 7700898)
1. An effective and safe marrow purging strategy using a lethally irradiated killer T cell clone.
Cesano A; Pierson G; Santoli D
Prog Clin Biol Res; 1994; 389():165-73. PubMed ID: 7700898
[No Abstract] [Full Text] [Related]
2. Expansion and activation of human natural killer cells as therapy for autologous transplantation.
Miller JS; Verfaillie C; McGlave P
Prog Clin Biol Res; 1994; 389():39-45. PubMed ID: 7700914
[No Abstract] [Full Text] [Related]
3. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
[TBL] [Abstract][Full Text] [Related]
4. Effects of ultraviolet B irradiation on human natural killer cell and lymphokine activated killer cell activity: therapeutic potential in bone marrow transplantation and tumor immunotherapy.
Yaron I; Zakheim AR; Oluwole SF; Hardy MA
Transplant Proc; 1995 Feb; 27(1):1379. PubMed ID: 7878918
[No Abstract] [Full Text] [Related]
5. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Klingemann HG; Wong E; Maki G
Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
[TBL] [Abstract][Full Text] [Related]
6. The effect of DNAse on the detection of residual malignant cells by polymerase chain reaction after immunologic purging of autologous bone marrow grafts.
Vervoordeldonk SF; Merle PA; Steenbergen EJ; van Leeuwen EF; von dem Borne AE; Slaper-Cortenbach IC
Prog Clin Biol Res; 1994; 389():601-9. PubMed ID: 7700926
[No Abstract] [Full Text] [Related]
7. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
Verma UN; Bagg A; Brown E; Mazumder A
Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
[TBL] [Abstract][Full Text] [Related]
9. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
Maki G; Tam YK; Berkahn L; Klingemann HG
Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
[TBL] [Abstract][Full Text] [Related]
11. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Klingemann HG; Deal H; Reid D; Eaves CJ
Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.
Casorati G; Locatelli F; Pagani S; Garavaglia C; Montini E; Lisini D; Turin I; Rossi F; Dellabona P; Maccario R; Montagna D
Exp Hematol; 2005 Feb; 33(2):212-8. PubMed ID: 15676215
[TBL] [Abstract][Full Text] [Related]
14. Effect of heat-pretreatment on interleukin-2-activated killer cells for in vitro purging.
Tanaka M; Honda J; Imamura Y; Shiraishi K; Tanaka K; Oizumi K
Pathobiology; 2000; 68(3):124-8. PubMed ID: 11174069
[TBL] [Abstract][Full Text] [Related]
15. Autologous bone marrow purging by lymphokine-activated killer cells: rationale and prospects.
Nasr S; Sabio H; Ades EW
Pathol Immunopathol Res; 1988; 7(6):477-82. PubMed ID: 3070531
[No Abstract] [Full Text] [Related]
16. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
Wong EK; Eaves C; Klingemann HG
Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
[TBL] [Abstract][Full Text] [Related]
17. Autologous bone marrow purging with LAK cells.
Giuliodori L; Moretti L; Stramigioli S; Luchetti F; Annibali GM; Baldi A
Int J Artif Organs; 1993 Dec; 16 Suppl 5():108-10. PubMed ID: 8013966
[TBL] [Abstract][Full Text] [Related]
18. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
[TBL] [Abstract][Full Text] [Related]
19. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation.
Tam YK; Klingemann HG
Biol Blood Marrow Transplant; 1999; 5(4):231-42. PubMed ID: 10465103
[TBL] [Abstract][Full Text] [Related]
20. New approaches for bone marrow purging.
Beaujean F; Hervé P
Transfus Sci; 1992; 13(4):431-42. PubMed ID: 10150140
[No Abstract] [Full Text] [Related]
[Next] [New Search]